Journal List > J Korean Diabetes Assoc > v.30(5) > 1062398

TOOLS
Park, Kim, Kim, Kim, Kim, Min, Park, Park, Baik, Son, Ahn, Oh, Lee, Lee, Chung, Choi, and Choi: Current Status of Aspirin User in Korean Diabetic Patients Using Korean Health Insurance Database
Original Article
The Journal of Korean Diabetes Association

The Journal of Korean Diabetes Association 2006; 30(5): 363-371.

Published online: 30 September 2006

DOI: https://doi.org/10.4093/jkda.2006.30.5.363

Current Status of Aspirin User in Korean Diabetic Patients Using Korean Health Insurance Database

Ie Byung Park*, 1, Dae Jung Kim*, 2, Jaiyong Kim*, **, Hyeyoung Kim**, Hwayoung Kim*, **, Kyung Wan Min*, 3, Seok Won Park*, 4, Jeong Hyun Park*, 5, Sei Hyun Baik*, 6, Hyun Shik Son*, 7, Chul Woo Ahn*, 8, Jee-Young Oh*, 9, Sunhee Lee**, Juneyoung Lee*, 10, Choon Hee Chung*, 11, Injeoung Choi**, Kyung Mook Choi*, 6

*Task Force Team for Basic Statistical Study of Korean Diabetes Mellitus of Korean Diabetes Association, Korea.

**Department of Research, Health Insurance Review Agency, Korea.

1Department of Endocrinology, Gachon University of Science and Medicine, Gil Medical Center, Korea.

2Department of Endocrinology and Metabolism, Ajou University School of Medicine, Korea.

3Department of Internal Medicine, College of Medicine, Eulji University, Korea.

4Department of Internal Medicine, Pochon CHA University, Korea.

5Department of Internal Medicine, Pusan Paik Hospital, Inje College of Medicine, Korea.

6Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University, Korea.

7Department of Internal Medicine, The Catholic University of Korea, Korea.

8Department of Internal Medicine, Yonsei University College of Medicine, Korea.

9Division of Endocrinology and Metabolism, Ewha Womans University College of Medicine, Korea.

10Department of Biostatistics, College of Medicine, Korea University, Korea.

11Department of Internal Medicine, Wonju College of Medicine, Yonsei University, Korea.

Received 4 August 2006       Accepted 28 September 2006

Copyright © 2006 Korean Diabetes Association

Abstract

Aims

ADA guidelines recommend aspirin for all patients with diabetes who have had a prior CHD events as well as a primary prevention strategy among those with at least one other risk factor. We examined the current status of regular aspirin intake among Korean adults who diagnosed as diabetes.

Methods

This study examined the characteristics of aspirin user in new-onset diabetes over 40 years based on health insurance claims submitted to the Health Insurance Review Agency (HIRA) of Korea during the period from January 2001 through December 2003. New onset diabetes defined as the first health insurance claim of antidiabetic drugs submitted to HIRA for the three months (January to March 2001) that never submitted for previous 6 years.

Results

The number of total new-onset diabetic patients was 30,014 in 2001, 29,819 in 2002, and 32,061 in 2003. The incidence rate of diabetes over 40 years for 3 months in 2001, 2002 and 2003 were 0.172%, 0.167% and 0.18. Mean age of women who diagnosed diabetes were significant higher than that of men in 2001 (women 59.2 ± 10.6 yrs, men 54.8 ± 9.8 yrs), in 2002 (women 59.5 ± 10.6 yrs, men 54.6 ± 9.3 yrs) and in 2003 (women 59.6 ± 10.7 yrs, men 54.7 ± 9.9 yrs) (p < 0.001).
The number of aspirin user increased from 2,065 (6.9%) in 2001, 2,638 (8.9%) in 2002 and 3,711 (11.6%) in 2003. 30.5% of new-onset diabetics in 2001 had hypertension, 12.4% of them had hypercholesterolemia, 11.8% of them had cerebral infarct, 2.6% of them had cerebral hemorrhage, 3.8% of them had coronary heart disease and, but, 55.6% of them had not any CVD. Logistic regression analysis using aspirin use as a dependent variable showed that the number of aspirin use in patients with hypertension, hypercholesterolemia, cerebral infarct and coronary heart disease was higher than in patients without those (hypertension [OR], 3.89 (95% CI, 3.52~4.31); hypercholesterolemia [OR], 2.16 (95% CI, 1.90~2.46; cerebral infarct [OR], 2.05 (95% CI, 1.82~2.30); coronary heart disease [OR], 9.41 (95% CI, 8.20~10.80), respectively). Coronary heart disease was the most important associated factor of aspirin use.

Conclusion

We found significant underuse of aspirin therapy among our population compared with that of America. Major efforts are needed to increase aspirin use in diabetic patients.

Keywords: Aspirin, Cardiovascular disease, Diabetes

Figures and Tables

Table 1
Basal Characteristics of the Patients with Newly Diagnosed Diabetes from 2001 to 2003
jkda-30-363-i001

*CVD, cardiovascular disease.

Table 2
Comparison between Men and Women with Newly Diagnosed Diabetes in 2001
jkda-30-363-i002

NS, not significant.

Table 3
Comparison of Clinical Characteristics between Aspirin User and Non-user in 2001
jkda-30-363-i003

*CVD, cardiovascular disease.

Table 4
Logistic Regression Analysis using Aspirin Use as a Dependent Variable in 2001
jkda-30-363-i004

References

1. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993. 16:434–444.
2. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998. 339:229–234.
3. American Diabetes Association. Standards of medical care in diabetes2006. Diabetes Care. 2006. S4–S42.
4. Colwell JA, Nesto RW. The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care. 2003. 26:2181–2188.
5. US Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med. 2002. 136:157–160.
6. The ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus: Early Treatment Diabetic Retinopathy Study report 14. JAMA. 1992. 268:1292–1300.
7. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial: HOT study group. Lancet. 1998. 351:1755–1762.
8. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994. 308:81–106.
9. Rolka DB, Fagot-Campagna A, Narayan KM. Aspirin use among adults with diabetes: estimates from the Third National Health and Nutrition Examination Survey. Diabetes Care. 2001. 24:197–201.
10. Krein SL, Vijan S, Pogach LM, Hogan MM, Kerr EA. Aspirin Use and Counseling About Aspirin Among Patients With Diabetes. Diabetes Care. 2002. 25:965–970.
11. International Diabetes Federation. Diabetes Atlas. 2003. 2nd ed. Belgium: International Diabetes Federation;17–71.
12. Kim SM, Lee JS, Lee J, Na JK, Han JH, Yoon DK, Baik SH, Choi DS, Choi KM. Prevalence of diabetes and impaired fasting glucose in Korea: Korean National Health and Nutrition Survey 2001. Diabetes Care. 2006. 29:226–231.
15. Shin CS, Lee HK, Koh C-S, Kim YI, Shin YS, Yoo KY, Paik HY, Park YS, Yang BG. Risk factors for the development of NIDDM in Yonchon County, Korea. Diabetes Care. 1997. 20:1842–1846.
16. Morimoto T, Fukui T, Lee TH, Matsui K. Application of U.S. guidelines in other countries: aspirin for the primary prevention of cardiovascular events in Japan. Am J Med. 2004. 117:459–468.
17. Rodondi N, Bauer DC. Assessing the risk/benefit profile before recommending aspirin for the primary prevention of cardiovascular events. Am J Med. 2004. 117:528–530.
TOOLS
Similar articles